The prestigious journal Oncotarget has published a study conducted by the Catalan Institute of Oncology (ICO), Takeda, Anaxomics Biotech and the Pompeu Fabra University Research Group on Structural Bioinformatics that compares the mechanisms of action of brigatinib and alectinib to first-line drugs for lung-cancer patients with ALK gene rearrangement.

The study was carried out with Anaxomics TPMS (Therapeutic Performance Mapping System) technology based on systems biology and artificial intelligence. TPMS can be used in different phases of drug development and in this study was used to simulate patients with ALK+ lung cancer treated with the drugs above.

Enric Carcereny of ICO-Germans Trias i Pujol University Hospital participated in the study.

Carcereny, E; Fernández-Nistal, A.; López, A.; Montoto, C.; Naves, A.; Segú-Vergés, C.; Coma, M.; Jorba, G.; Oliva, B.; Mas, J.M. Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology based approach. Oncotarget, 2021 https://doi.org/10.18632/oncotarget.27875

You may also be interested in:

• Anaxomics inaugurates headquarters in Barcelona to continue growth in 2020
• Anaxomics artificial intelligence used for new malaria and diabetes studies